top of page

The Rejection of the Bedaquiline Patent Opposition in Indonesia Raises the Risk of Difficulty in Accessing Optimal TB Therapy

The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, in the context of this article, will be referred to as ‘Bedaquiline’). The patent opposition was filed to the Patent Appeal Commission, Directorate General of Intellectual Property (DGIP), Ministry of Law and Human Rights. The patent opposition was submitted in November 2022 and was rejected by a decision from the Judiciary Panel on November 9th, 2023. Read more here.

40 views0 comments

Recent Posts

See All

Treat Action Group 2023 Pipeline Report

Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full


bottom of page